SynapDx Corporation Raises US$9 Million in Series A Funding

Company to Develop Proprietary Technologies for the Early Detection of Autism

WALTHAM, Massachusetts, June 1, 2010 - SynapDx Corp., a new company focused on developing and commercializing
diagnostic testing for the early detection of autism, announced the
completion of a US$9 million Series A financing by Bain Capital Ventures,
General Catalyst Partners, and North Bridge Venture Partners.

"Autism has a profound effect on children and their families," said
Stanley N. Lapidus, the company's founder, President and Chief Executive
Officer. "The right objective blood-based diagnostic test for autism may help
achieve earlier diagnosis, more rapid intervention, and improved outcomes."

About SynapDx Corp.

SynapDx was formed to develop and commercialize blood-based diagnostic
tests for the early detection of autism. SynapDx was founded by Stanley N.
Lapidus, an experienced life-sciences entrepreneur and inventor with 31
issued patents. Mr. Lapidus founded and led Cytyc Corp., EXACT Sciences
Corp., and Helicos BioSciences Corp. Mr. Lapidus' co-founders of SynapDx
Corp. include Jeffrey R. Luber, Esq. and Patrick A. Anquetil, PhD.

www.synapdx.com

Media: +1-781-466-7870, preferred method: info at synapdx.com